MASIMO CORPORATION

Masimo Corporation is a global leader in noninvasive patient monitoring solutions, specializing in innovative pulse oximetry, vital sign monitoring, and brain function monitoring technologies. Founded on breakthrough accuracy in pulse oximetry (Masimo SET®), the company develops and manufactures continuous monitoring systems for hospitals, ICUs, operating rooms, and neonatal care settings. Core product lines include Masimo SET® Pulse Oximetry for continuous, accurate oxygen saturation measurement across all patient populations and clinical settings; SedLine® Brain Function Monitoring for depth-of-anesthesia and sedation monitoring; Masimo O3® Regional Oximetry for tissue oxygenation assessment with FDA-cleared hemoglobin parameters; and Root® Patient Monitoring and Connectivity Platform, a modular hospital automation system integrating vital signs, connectivity, and clinical workflow solutions. Masimo technologies are deployed across acute care, perioperative, emergency, neonatal, and general floor environments. The company holds over 900 patents globally and serves leading hospitals and healthcare systems in 30+ countries. Known for motion-artifact rejection and performance accuracy across diverse patient populations, Masimo's solutions address clinical needs in congenital heart disease screening, critical care monitoring, anesthesia management, and cost reduction through early patient distress detection. The company emphasizes sustainability and has strategic partnerships with major healthcare technology providers including Philips. Acquired by Danaher in February 2026.